Carolina based biomarker data management, visualization, and analysis firm OmicSoft has announced the latest release of its flagship software product Array Suite 9.0. The suite encapsulates Array Studio, the GUI for Next Generation Sequencing (NSG) and comprehensive visual OMIC analysis tool, and Array Server, which pose as back-end solution for project management, sample management, data storage and Land database. Both the services are compatible across the enterprise server or the virtual private cloud powered by Amazon and EC2. The cloud platform would offer an additional encrypted layer of security while eliminating the need to house the supporting hardware on premise.
"Array Suite 9.0 is a huge advancement in OmicSoft's product lines, and is built with exciting new features for variant annotation, GWAS data analysis, and more. I am very much looking forward to getting this in the hands of our customers, as we're very proud of our achievements over the past year," said Jack Liu, President of OmicSoft Corporation.
The new variant annotation system allows users to upload their genetic data and comprehensively search, annotate and filter using public domain resources. The variant annotation system provides the backbone of OmicSoft's GeneticsLand solution, allowing full analysis and management of GWAS and eQTL data types. The version is also said to comprise of a wide range of new visualizations and analytics improvements and advancements for RNA-Seq, DNA-Seq, and clinical data management.
OmicSoft was cofounded in 2007 by Jack Liu with Array Studio designed to work with gene expression products that gradually expanded to the current capability it boasts. Array Server was released in 2008 and the suite now serves as a backbone of the company’s data and service offerings, including ImmunoLand, CVMLand, and GeneticsLand. The services have been widely used by pharmaceutical and biotech companies as well as academic institutions.
OmicSoft’s disease centric approach in developing software and data services allows customers to focus on disease area of interest while enabling cross disease research. It accelerates customer’s reach in a variety of areas including pharmacogenetics, Cancer Genomics, Immunology, and Cardiovascular and Metabolic disease. The latest update is expected to enhance this further.